SCHEMBL5114271

SCHEMBL5114271

CC(C)(C)OC(=O)N[C@@H](CSCC1CCCCC1)C(=O)NC1CCN(C(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.46
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
NAMPT P43490 1/20 0.42
HRH2 P25021 2/20 0.41
HRH1 P35367 2/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
MEN1 O00255 3/20 0.40
RAB9A P51151 1/20 0.40
SCN9A Q15858 2/20 0.40
NPC1L1 Q9UHC9 1/20 0.39
PRKAA2 P54646 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5114334 0.91 EPHX2 (0.49) EPHX2HDAC4HDAC1HDAC6ALDH1A1
SCHEMBL5118768 0.87 SIGMAR1 (0.43) HDAC4HDAC1HDAC6HRH2HRH1
SCHEMBL5117829 0.85 CACNA1B (0.47) EPHX2ALDH1A1LMNAKMT2AMEN1
SCHEMBL5351866 0.82 HDAC4 (0.51) HDAC4HDAC1HDAC6HRH2HRH1
SCHEMBL5114278 0.82 EPHX2 (0.47) EPHX2HDAC4HDAC1HDAC6ALDH1A1
SCHEMBL5351299 0.81 HDAC4 (0.45) HDAC4HDAC1HDAC6HRH2HRH1
SCHEMBL5110130 0.80 CYP2C19 (0.51) HDAC4HDAC1HDAC6ALDH1A1KMT2A
SCHEMBL5124066 0.80 CYP2C19 (0.51) HDAC4HDAC1HDAC6ALDH1A1KMT2A
SCHEMBL5117778 0.80 CYP2C19 (0.51) HDAC4HDAC1HDAC6ALDH1A1KMT2A
SCHEMBL14210101 0.80 CYP2C19 (0.51) HDAC4HDAC1HDAC6ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351721-B2 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. (JP) 2008-04-01 US claimed
US-20030232806-A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. 2003-12-18 US claimed
EP-1090912-A1 AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-04-11 EP claimed
US-7351721-B2 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. (JP) 2008-04-01 US disclosed
US-7351721-B2 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. (JP) 2008-04-01 US disclosed
US-7351721-B2 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. (JP) 2008-04-01 US disclosed
US-20030232806-A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. 2003-12-18 US disclosed
US-6605608-B1 Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors ONO PHARMACEUTICAL CO., LTD (JP) 2003-08-12 US disclosed
EP-1090912-A1 AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232806-A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them CACNA1I, CACNA1S, CACNA1B EPHX2 2908/4885HDAC4 4261/4885HDAC1 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.